Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | MGLL | Q99685 | 7/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | DUSP1 | P28562 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18426988 | 0.89 | LMNA (0.56) | FASNSMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL22722816 | 0.88 | ALDH1A1 (0.56) | FASNSMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL23542090 | 0.83 | NPC1 (0.52) | FASNSMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL1675466 | 0.82 | HPSE (0.64) | SMN1; SMN2KMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL28266926 | 0.81 | KDM4E (0.62) | SMN1; SMN2KMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL11371944 | 0.81 | MAPT (0.57) | SMN1; SMN2KMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL2855757 | 0.81 | MAPT (0.57) | SMN1; SMN2KMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL1675412 | 0.81 | NPC1 (0.60) | SMN1; SMN2KMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL16149315 | 0.81 | FASN (0.73) | FASNSMN1; SMN2ALDH1A1HPGDNPC1 | |
| SCHEMBL19919312 | 0.81 | MAPT (0.52) | FASNSMN1; SMN2KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142910-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANDOS BIOPHARMA, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230142910-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANDOS BIOPHARMA, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-11571419-B2 | Lanthionine synthetase C-like 2-based therapeutics | LANDOS BIOPHARMA, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| EP-3757099-B1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANDOS BIOPHARMA INC (US) | 2022-06-01 | — | — | EP | disclosed |
| US-11197891-B2 | Therapies with lanthionine C-like protein 2 ligands and cells prepared therewith | LANDOS BIOPHARMA, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20210046070-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANDOS BIOPHARMA, INC. (US) | 2021-02-18 | — | — | US | disclosed |
| EP-3757099-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANDOS BIOPHARMA, INC. (US) | 2020-12-30 | — | — | EP | disclosed |
| US-10849895-B2 | Lanthionine synthetase C-like 2-based therapeutics | LANDOS BIOPHARMA, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| EP-3209655-B1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANDOS BIOPHARMA INC (US) | 2020-07-15 | — | — | EP | disclosed |
| US-10682349-B2 | Lanthionine synthetase C-like 2-based therapeutics | LANDOS BIOPHARMA, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20180055841-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANDOS BIOPHARMA, INC. (US) | 2018-03-01 | — | — | US | disclosed |
| US-20180055841-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANDOS BIOPHARMA, INC. (US) | 2018-03-01 | — | — | US | disclosed |
| US-9839635-B2 | Lanthionine synthetase C-like 2-based therapeutics | LANDOS BIOPHARMA, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-9839635-B2 | Lanthionine synthetase C-like 2-based therapeutics | LANDOS BIOPHARMA, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170119762-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | BIOTHERAPEUTICS, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170119762-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | BIOTHERAPEUTICS, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-9556146-B2 | Lanthionine synthetase C-like 2-based therapeutics | BIOTHERAPEUTICS, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556146-B2 | Lanthionine synthetase C-like 2-based therapeutics | BIOTHERAPEUTICS, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160115153-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | BIOTHERAPEUTICS, INC. (US) | 2016-04-28 | — | — | US | disclosed |
| US-20160115153-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | BIOTHERAPEUTICS, INC. (US) | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210046070-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANCL2, CBS, LCP2 | FASN 743/4885SMN1; SMN2 2854/4885KMT2A 2759/4885 |
| US-20180055841-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANCL2, CBS, LCP2 | FASN 743/4885SMN1; SMN2 2854/4885KMT2A 2759/4885 |
| US-20160115153-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANCL2, CBS, LCP2 | FASN 743/4885SMN1; SMN2 2854/4885KMT2A 2759/4885 |
| US-11571419-B2 | Lanthionine synthetase C-like 2-based therapeutics | LANCL2, CBS, LCP2 | FASN 743/4885SMN1; SMN2 2854/4885KMT2A 2759/4885 |
| US-10682349-B2 | Lanthionine synthetase C-like 2-based therapeutics | LANCL2, CBS, LCP2 | FASN 743/4885SMN1; SMN2 2854/4885KMT2A 2759/4885 |
| US-11197891-B2 | Therapies with lanthionine C-like protein 2 ligands and cells prepared therewith | LCP2, LANCL2, CALCB | FASN 1404/4885SMN1; SMN2 2980/4885KMT2A 3249/4885 |
| US-20230142910-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANCL2, CBS, LCP2 | FASN 743/4885SMN1; SMN2 2854/4885KMT2A 2759/4885 |
| US-10849895-B2 | Lanthionine synthetase C-like 2-based therapeutics | LANCL2, CBS, LCP2 | FASN 743/4885SMN1; SMN2 2854/4885KMT2A 2759/4885 |
| US-20170119762-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANCL2, CBS, LCP2 | FASN 743/4885SMN1; SMN2 2854/4885KMT2A 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.